			Home About us Contact

Dysphoric Disorder (dysphoric + disorder)

Distribution by Scientific Domains

Medical Sciences	70%
Psychology	30%

Kinds of Dysphoric Disorder

premenstrual dysphoric disorder

Selected Abstracts

Selective Serotonin Reuptake Inhibitors and Treatment of Premenstrual Dysphoric Disorder

PERSPECTIVES IN PSYCHIATRIC CARE, Issue 2 2002
AP/MHCNS, Deborah L. Finfgeld RN
TOPIC. Premenstrual dysphoric disorder (PMDD) has reentered the spotlight following the FDA's recent approval of fluoxetine hydrochloride to treat its symptoms. Although the diagnosis and treatment of PMDD has long been a source of contention, the FDA move has heightened the debate over this diagnostic category and the most appropriate treatment. PURPOSE. To explore several diagnoses related to PMDD and review recent research findings pertaining to the effectiveness of SSRIs to treat PMDD. SOURCES OF INFORMATION. Published literature. CONCLUSIONS. Advanced practice nurses need to remain well informed about premenstrual conditions and emerging evidence-based treatment alternatives. In particular, they need to remember that the FDA has approved fluoxetine for the treatment of a very small subset of women with premenstrual complaints, among whom treatment efficacy is limited. [source]

Differentiating Premenstrual Dysphoric Disorder From Premenstrual Exacerbations of Other Disorders: A Methods Dilemma

CLINICAL PSYCHOLOGY: SCIENCE AND PRACTICE, Issue 2 2001
Shirley Ann Hartlage
Premenstrual dysphoric disorder (PMDD) and premenstrual exacerbations of other disorders are difficult to distinguish. Previous methods, such as excluding women with other disorders from a PMDD diagnosis, do not enable a dual diagnosis. Our objective is to advance conceptual and clinical thinking and stimulate dialogue regarding this methods dilemma. The discussion sheds light on comorbidity in general, regardless of the disorders. Considering fundamental criteria for severe premenstrual disorders helps distinguish the phenomena of interest. A proposed method allows identification of PMDD co-occurring with other disorders. PMDD symptoms can be differentiated by their nature and timing (e.g., cyclic depressed mood could be a PMDD symptom, but cyclic binge eating or depressed mood all month long could not be). Impairment must increase premenstrually for a PMDD diagnosis. The proposed method is an advance, but specified unanswered questions remain. [source]

How does premenstrual dysphoric disorder relate to depression and anxiety disorders?

DEPRESSION AND ANXIETY, Issue 3 2003
Mikael Landén M.D., Ph.D.
Abstract Premenstrual dysphoric disorder (PMDD) is a severe variant of premenstrual syndrome that afflicts approximately 5% of all women of fertile age. The hallmark of this condition is the surfacing of symptoms during the luteal phase of the menstrual cycle, and the disappearance of symptoms shortly after the onset of menstruation. Whereas many researchers have emphasized the similarities between PMDD and anxiety disorders, and in particular panic disorder, others have suggested that PMDD should be regarded as a variant of depression. Supporting both these notions, the treatment of choice for PMDD, the serotonin reuptake inhibitors (SRIs), is also first line of treatment for depression and for most anxiety disorders. In this review, the relationship between PMDD on the one hand, and anxiety and depression on the other, is being discussed. Our conclusion is that PMDD is neither a variant of depression nor an anxiety disorder, but a distinct diagnostic entity, with irritability and affect lability rather than depressed mood or anxiety as most characteristic features. The clinical profile of SRIs when used for PMDD, including a short onset of action, suggests that this effect is mediated by other serotonergic synapses than the antidepressant and anti-anxiety effects of these drugs. Although we hence suggest that PMDD should be regarded as a distinct entity, it should be emphasized that this disorder does display intriguing similarities with other conditions, and in particular with panic disorder, which should be the subject of further studies. Also, the possibility that there are subtypes of PMDD more closely related to depression, or anxiety disorders, than the most common form of the syndrome, should not be excluded. Depression and Anxiety 17:122,129, 2003. © 2003 Wiley-Liss, Inc. [source]

Characteristics of women seeking treatment for premenstrual syndrome in Taiwan

ACTA PSYCHIATRICA SCANDINAVICA, Issue 2 2002
Mei-Chun Hsiao
Objective:,To analyze the characteristics of 150 women who visited a premenstrual syndrome (PMS) clinic in a Taiwanese medical center staffed by both psychiatrists and gynecologists. Method:,All subjects were interviewed and assessed for premenstrual dysphoric disorder (PMDD) using DSM-IV criteria, a PMS questionnaire, and the structured Mini-International Neuropsychiatric Interview (MINI). Where PMDD was suspected, subjects were followed using a daily symptom record. Results:,A total of 110 subjects (73%) met the ICD-10 criteria for PMS. The most common PMS symptoms were minor psychological discomfort, muscular tension, and aches or pains. For 129 subjects (86%), other concurrent psychiatric disorders were diagnosed using the MINI. Of these, 48 (37%) reported premenstrual exacerbation (PME) of a previously diagnosed psychiatric condition. Conclusion:,The results of this study indicate that women who complain of PMS may be at a high risk of other psychiatric dysfunction, especially mood disorder. Further, the high proportion of PME cases determined in this study suggests that further investigation is required. [source]

Menstrual Migraine: Case Studies of Women with Estrogen-Related Headaches

HEADACHE, Issue 2008
Susan L. Hutchinson MD
This paper presents 2 case scenarios that illustrate the complexity of diagnosing and managing migraine associated with hormonal changes. Migraine is commonly associated with comorbidies such as depression, anxiety, obesity, cardiovascular disease, as well as other conditions, thereby making management more challenging for the physician and the patient. The first case is a 35-year-old woman who has migraine almost exclusively during menstruation. She is under a physician's care for long-term management of premenstrual dysphoric disorder (PMDD). Achieving a differential diagnosis of pure menstrual migraine is illustrated, and a detailed treatment plan including use of a migraine miniprophylaxis protocol, management of her PMDD, and prescription of acute treatment medications is reviewed. The second case scenario describes the diagnosis of menstrually associated migraine in a woman who suffers from a frequent disabling migraine along with work-related anxiety and depression. This paper reviews her differential diagnosis, laboratory testing, treatment plan, including management of her comorbid anxiety and depressive symptoms. [source]

Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review

HUMAN PSYCHOPHARMACOLOGY: CLINICAL AND EXPERIMENTAL, Issue 3 2003
*Article first published online: 11 DEC 200, Michel Bourin
Abstract Paroxetine is a potent selective serotonin reuptake inhibitor (SSRI) with indications for the treatment of depression, obsessive, compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, post-traumatic stress disorder, premenstrual dysphoric disorder and chronic headache. There is wide interindividual variation in the pharmacokinetics of paroxetine in adults as well as in the elderly with higher plasma concentrations and slower elimination noted in the latter. Elimination is also reduced in severe renal and hepatic impairment, however, serious adverse events are extremely rare even in overdose. A Pub Med search was used to collect information on the efficacy and tolerability in elderly patients. There are few studies of depression in the elderly and only one study in the old,old. In anxiety disorders including general anxiety disorder, panic disorder, obsessive,compulsive disorder and social anxiety, there are no studies at all in the elderly. However, the safety of the drug allows its prescription in the elderly. In summary, paroxetine is well tolerated in the treatment of depression in those between the ages of 65 and 75, although few studies have examined its use in those of 75 and older. Copyright © 2002 John Wiley & Sons, Ltd. [source]

Conflict resolution in women is related to trait aggression and menstrual cycle phase

AGGRESSIVE BEHAVIOR, Issue 3 2003
Alyson J. Bond
Abstract Twenty-four women with a diagnosis of premenstrual dysphoric disorder (PMDD) and 18 controls took part in a study of patterns of female aggression. They completed a version of the Conflict Tactics Scale for a premenstrual and a follicular phase of their menstrual cycle and for the past year. The Life History of Aggression was completed during a clinician interview. The women used more aggressive tactics to solve conflicts in the premenstrual than in the follicular phase, but the difference was only significant for the PMDD group. During the past year, reasoning was the most common strategy used by women to resolve conflicts, but verbal aggression was also prevalent. Although physical violence was less common, the prevalence of any act of violence was 33% in the controls and 62% in the clinical group. Women with PMDD used both verbal and physical aggression more frequently than the controls and had a higher lifetime history of aggression. Aggression by women toward partners was associated with a general tendency to act aggressively. Aggr. Behav. 29:228,238, 2003. © 2003 Wiley-Liss, Inc. [source]